Table 3.
Subgroup analysis of the benefit of the fifth chemotherapy according to tumor stage, D90 CTVHR, CTVHR volume, pelvic nodal status and neutrophils count. Hazard ratio for death/event are given (95% CI confidence intervals) (n = 209).
| FIGO < IIIA | FIGO ≥ IIIA | N0 | N1 | Neutrophils ≤ 7500/mm3 | |
| OS | 0.278 (0.142–0.546) * | 0.704 (0.271–10.827) | 0.373 (0.169–0.823)* | 0.329 (0.152–0.710) * | 0.285 (0.126–0.646) * |
| PFS | 0.344 (0.19–0.617) * | 0.682 (0.310–10.498) | 0.383 (0.192–0.765)* | 0.412 (0.215–0.791) * | 0.415 (0.214–0.808) |
| LFS | 0.319 (0.165–0.616) * | 0.562 (0.223–10.417) | 0.389 (0.184–0.824)* | 0.307 (0.142–0.663) * | 0.298 (0.133–0.660) |
| LRFS | 0.343 (0.186–0.343) * | 0.703 (0.303–10.630) | 0.382 (0.190–0.768)* | 0.408 (0.203–0.822) | 0 |
| DMFS | 0.344 (0.180–0.655) * | 0.542 (0.237–10.236) | 0.327 (0.155–0.689)* | 0.386 (0.194–0.770) * | 0.369 (0.176–0.774) |
| LC | 0.340 (0.127–0.914) * | 0.346 (0.082–10.452) | 0.340 (0.127–0.914)* | 0.264 (0.080–0.865) * | 0.301 (0.091–988) |
| LRC | 0.439 (0.214–0.898) * | 0.582 (0.218–10.554) | 0.388 (0.170–0.886)* | 0.475 (0.213–10.059) | 0.482 (0.215–0.10.083) |
| DMC | 0.286 (0.110–0.742) * | 0.478 (0.187–10.223) | 0.193 (0.069–0.545)* | 0.401 (0.165–0.974) | |
| CTVHR ≤ 25cm3 | CTVHR > 25cm3 | D90 CTVHR ≤ 80GyEQD2 | D90 CTVHR > 80GyEQD2 | Neutrophils > 7500/mm3 | |
| OS | 0.569 (0.219–10.482) | 0.304 (0.149–0.622) * | 0.360 (0.179–0.723) * | 0.399 (0.157–10.014) | 0.464 (0.172–10.251) |
| PFS | 0.598 (0.263–10.359) | 0.369 (0.201–0.678) * | 0.411 (0.222–0.761) * | 0.431 (0.200–0.927) * | 0.481 (0.193–0.1198) |
| LFS | 0.482 (0.195–10.195) | 0.339 (0.171–0.674) * | 0.402 (0.205–0.789) * | 0.341 (0.139–0.834) * | 0.536 (0.203–10.412) |
| LRFS | 0.664 (0.279–10.579) | 0.346 (0.182–0.658) * | 0.433 (0.231–0.813) * | 0.415 (0.183–0.939) * | 0.489 (0.193–10.242) |
| DMFS | 0.583 (0.242–10.407) | 0.310 (0.161–0.597) * | 0.348 (0.183–0.662) * | 0.437 (0.185–10.031) | 0.442 (0.174–10.124) |
| LC | 0.365 (0.103–10.295) | 0.325 ( 0.112–0.938) * | 0.379 (0.137–10.048) | 0.289 (0.078–10.076) | 0.769 (0.140–40.224) |
| LRC | 0.611 (0.237–10.574) | 0.406 (190–864) * | 0.488 (0.232–10.028) | 0.434 (0.173–10.088) | 0.640 (0.209–10.959) |
| DMC | 0.429 (0.143–10.280) | 0.260 (0.107–0.634) * | 0.303 (0.132–0.697) * | 0.330 (0.105–10.040) | 0.302 (0.091–10.128) |
SE: standard error; OS: overall survival; PFS: progression free survival; LFS: local free survival; RFS: regional free survival; LRFS: loco-regional free survival; DMFS: distant metastasis free survival; DC: disease control; LC: local control; RC: regional control; LRC: loco-regional control; LRC: loco-regional control; DMC: distant metastatic control; *: significant values.